Search Results - "Overgaard RV"

A sensitive LC-MS/MS method for tirzepatide in rat plasma with comprehensive pharmacokinetic evaluation.

Authors: Song, Sungmin Hyeon, Minju Kim, Siyeon et al.

Source: Journal of Analytical Science & Technology. 3/18/2026, Vol. 17 Issue 1, p1-10. 10p.

Oral Semaglutide as an Opportunity for an Appropriate Therapeutic Switch in People with Type 2 Diabetes: A Delphi Consensus.

Authors: Bruglia, Matteo Cardini, Francesca Di Luzio, Raffaella et al.

Source: Diabetes Therapy. Aug2025, Vol. 16 Issue 8, p1707-1725. 19p.

Exploring the Efficacy and Safety of Tirzepatide in Obesity Management and Cardiometabolic Risk Factors: A Comprehensive Systematic Review and Meta‐Analysis.

Authors: Wang, Jian‐Ying Kang, Jyun‐Wei Peng, Tzu‐Rong et al.

Source: Clinical Obesity. Dec2025, Vol. 15 Issue 6, p1-13. 13p.

Implementing exposure limits for players in contact team sports: review of principles and practices.

Authors: Fuller, Colin W.¹ (AUTHOR) colinfullerconsultancy@gmail.com

Source: Frontiers in Sports & Active Living. 2025, p1-6.

Dose–Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis.

Authors: Builes-Montaño, Carlos E. Suarez-Rodriguez, Andres F. Alzate-Vinasco, Maria A.

Source: Diabetes Therapy. Jul2026, Vol. 17 Issue 7, p1067-1083. 17p.

Exposure-Response Analysis of Efsubaglutide Alfa in Patients with Type 2 Diabetes Mellitus.

Authors: Wang Q Jiang F Xu Y et al.

Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2025 Dec; Vol. 64 (12), pp. 1785-1797. Date of Electronic Publication: 2025 Oct 17.

Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study

Journal Info: Publisher: Adis, part of Springer Science+Business Media Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.

Authors: Fink-Jensen, Anders Wörtwein, Gitta Klausen, Mette Kruse et al.

Source: Psychopharmacology. Jan2025, Vol. 242 Issue 1, p63-70.

Cardioprotective effects of semaglutide on isolated human ventricular myocardium.

Authors: Krammer, Thomas Baier, Maria J. Hegner, Philipp et al.

Source: European Journal of Heart Failure. Jul2025, Vol. 27 Issue 7, p1315-1325. 11p.

Effects of insulin resistance and β-cell function on diabetic complications in Korean diabetic patients.

Authors: Song, Do Kyeong Hong, Young Sun Sung, Yeon-Ah et al.

Source: PLoS ONE. 10/22/2024, Vol. 19 Issue 10, p1-11. 11p.

Pioneering pharmacometrics practice in Korea: an eight-year retrospective analysis of 192 projects from the first dedicated service organization (2016–2024).

Authors: Lee, So Jin Bae, Soo Hyeon Park, Jinha et al.

Source: Translational & Clinical Pharmacology. Mar2026, Vol. 34 Issue 1, p15-34. 20p.

Effectiveness for adding or switching from other incretin‐related drugs to oral semaglutide in type 2 diabetes.

Authors: Oya, Junko Shimizu, Mika Kubota, Ryo et al.

Source: Journal of Diabetes Investigation. Apr2025, Vol. 16 Issue 4, p608-614. 7p.

Development and validation of a UPLC-HR-SIM method to quantify semaglutide for its pharmacokinetic study.

Authors: Xinyi Jiang Tong Li Meng Yu et al.

Source: Intelligent Pharmacy. Apr2025, Vol. 3 Issue 2, p143-149. 7p.

A self-unfolding polymer foil loaded with a permeation enhancer Ionogel for superior oral peptide delivery.

Authors: Raptis K McCabe R Rubio-Huertas M et al.

Source: Drug delivery and translational research [Drug Deliv Transl Res] 2026 Jul 23. Date of Electronic Publication: 2026 Jul 23.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE

Impact of sodium caprate dosed as a mini-tablet or suspension on insulin delivery and mucosa histomorphology.

Authors: Fredholt F Heade J Rantanen J et al.

Source: Drug delivery and translational research [Drug Deliv Transl Res] 2026 Jun; Vol. 16 (6), pp. 1773-1787. Date of Electronic Publication: 2025 Oct 08.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101540061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2190-3948 (Electronic) Linking ISSN: 2190393X NLM ISO Abbreviation: Drug Deliv Transl Res Subsets: MEDLINE

Population Pharmacokinetics of Efsubaglutide Alfa in Healthy Subjects and Subjects with Type 2 Diabetes.

Authors: Lou YR Xu YL Xiong Y et al.

Source: Clinical pharmacokinetics [Clin Pharmacokinet] 2025 Apr; Vol. 64 (4), pp. 533-552. Date of Electronic Publication: 2025 Feb 17.

Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Country of Publication: Switzerland NLM ID: 7606849 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1926 (Electronic) Linking ISSN: 03125963 NLM ISO Abbreviation: Clin Pharmacokinet Subsets: MEDLINE

Adherence and treatment discontinuation of oral semaglutide and once‐weekly semaglutide injection at 12 month follow‐up: Japanese real‐world data.

Authors: Horii, Takeshi Masudo, Chikako Takayanagi, Yui et al.

Source: Journal of Diabetes Investigation. Nov2024, Vol. 15 Issue 11, p1578-1584. 7p.

Efficacy of long‐term low carbohydrate diets for patients with type 2 diabetes: A systematic review and meta‐analysis.

Authors: Ichikawa, Takahiro Okada, Hiroshi Hironaka, Junya et al.

Source: Journal of Diabetes Investigation. Oct2024, Vol. 15 Issue 10, p1410-1421. 12p.

Exposure–response modeling for nausea incidence for cotadutide using a Markov modeling approach.

Authors: Yu, Hongtao Ueckert, Sebastian Zhou, Lina et al.

Source: CPT: Pharmacometrics & Systems Pharmacology. Sep2024, Vol. 13 Issue 9, p1582-1594. 13p.

Impact of Glucagon-like Peptide-1 Receptor Agonists on Intestinal Epithelial Cell Barrier.

Authors: Takizawa, Y. Kato, A. Onsui, A. et al.

Source: European Pharmaceutical Journal. Aug2024, Vol. 71 Issue 1, p43-52. 10p.

Oral Semaglutide: Dosage in Special Situations.

Authors: Kalra, Sanjay Kapoor, Nitin

Source: Diabetes Therapy. Jun2022, Vol. 13 Issue 6, p1133-1137. 5p.